VIVA|SCREEN
LIVE

Serial Number

79109519

Owner

VALNEVA

Attorney

Brewster Taylor

Filing Date

Nov 10, 2011

Add to watchlist:

No watchlists yet
View on USPTO

VIVA|SCREEN Trademark

Serial Number: 79109519 • Registration: 4277773

VIVA|SCREEN is a trademark filed by VALNEVA on November 10, 2011. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

VALNEVA (5 trademarks)

6 rue Alain Bombard

Entity Type: 99

VIVALIS (4 trademarks)

LIEUDIT LA CORBIÈRE
49450 ROUSSAY , FR

Entity Type: 11

Trademark Details

Filing Date

November 10, 2011

Registration Date

January 22, 2013

Published for Opposition

November 6, 2012

Cancellation Date

November 10, 2021

Goods & Services

Scientific apparatus and instruments, namely, typical equipment used in laboratories to take blood samples, to harvest biological cells, to select targeted cells, and microarrays chips for the identification and/or isolation of antibodies or the separation and recovery of cell clones producing antibodies in biological samples

Prophylactic and therapeutic medicines and pharmaceutical products for the prevention, diagnosis and cure of diseases that induce an immune response; Prophylactic and therapeutic veterinary products for the prevention, diagnosis and cure of diseases that induce an immune response; biological, biotechnological preparations and products obtained via genetic technology for medical or pharmaceutical purposes in the nature of preventing, diagnosing and curing diseases that induce an immune response; biological, biotechnological preparations and products obtained via genetic technology for veterinary purposes in the nature of preventing, diagnosing and curing diseases that induce an immune response; micro-organisms; cells; cell lines; viruses; nucleotides; plasmids; DNA or RNA sequences; antibodies; cell clones producing antibodies; vectors for therapy and diagnostic for medical purposes; molecules and antibodies, all for medical and pharmaceutical purposes in the nature of cell cultures, biochemical reagents, reagents for sample preparation, reagents for targeting and recovering targeted cells; biotechnological products for medical and pharmaceutical purposes in the nature of cell cultures, biochemical reagents, reagents for sample preparation, reagents for targeting and recovering targeted cells; products for diagnosis for medical and pharmaceutical purposes, namely, proteins, antibodies, and products comprising these molecules for the diagnosis of diseases that induce an immune response; prophylactic or therapeutic vaccines

Molecules obtained from biotechnologies, namely, proteins in raw material form for industrial use, scientific or medical research; biotechnological products for research and diagnosis, namely, chemicals, antibodies, antigens; micro-organisms, namely, cultures of microorganisms other than for medical and veterinary use; cells for scientific and laboratory uses; pre made and biological cell lines for scientific and laboratory uses; viruses for scientific and laboratory uses; nucleotides for use as biochemical reagents; plasmids for use as biochemical reagents; DNA or RNA sequences for use as biochemical reagents; antibodies for scientific and industrial research; cells for cloning for the production of antibodies; vectors for research and diagnosis; all of the previous products being not for medical or veterinary purposes; biological preparations for use in cell cultures other than for medical or veterinary purposes; bacteriological preparations for use in cell cultures other than for medical and veterinary use

Scientific services, namely, research and development of new products or process for production and/or purification of biological products for third parties; biological research; bacteriological, virology, immunology, biotechnology, genetic, medicine and pharmacology research; scientific research services for medical purposes; scientific research services for pharmaceutical purposes; scientific research services for veterinary purposes; development of new technologies for others in the field of biotechnology, biological and medical research; development of scientific and industrial research means inter alia to identify and isolate antibodies or cell clones producing antibodies

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 5, 2022 DENC
DEATH OF INTERNATIONAL REGISTRATION
Jun 5, 2022 DETH
TOTAL INVALIDATION PROCESSED BY THE IB
Jul 10, 2020 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Jun 8, 2020 INTS
INVALIDATION PROCESSED
Jun 8, 2020 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Apr 23, 2020 INTR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 26, 2019 NREP
CANCELLED SECTION 71
Aug 23, 2019 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 22, 2018 REM3
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 15, 2017 TCCA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 28, 2014 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
May 14, 2013 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 25, 2013 FICS
FINAL DISPOSITION PROCESSED
Apr 25, 2013 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 22, 2013 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Mar 2, 2013 NREP
REGISTERED-PRINCIPAL REGISTER
Jan 22, 2013 R.PR
NOTIFICATION PROCESSED BY IB
Dec 15, 2012 GPNX
PUBLISHED FOR OPPOSITION
Nov 6, 2012 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 17, 2012 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 17, 2012 OP2R
NOTICE OF PUBLICATION
Oct 17, 2012 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 28, 2012 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 21, 2012 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 21, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 21, 2012 CRFA
ASSIGNED TO LIE
Sep 20, 2012 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 19, 2012 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Sep 14, 2012 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 5, 2012 TCCA
NEW REPRESENTATIVE AT IB RECEIVED
Jul 27, 2012 NREP
REFUSAL PROCESSED BY IB
Apr 14, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 22, 2012 RFCS
REFUSAL PROCESSED BY MPU
Mar 22, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2012 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2012 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 20, 2012 MAFR
ASSIGNED TO EXAMINER
Mar 14, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 13, 2012 REPR